Canaccord lowered the firm’s price target on Cara Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm said at current levels, given the solidity of the Phase 2 data, they continue to believe the stock is significantly undervalued and are buyers of the shares into the 3Q readout.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CARA:
- Cara Therapeutics: Cash and cash equivalents sufficient for operations into 2026
- Cara Therapeutics reports Q4 EPS (59c), consensus (41c)
- Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
- Options Volatility and Implied Earnings Moves Today, March 04, 2024
- Options Volatility and Implied Earnings Moves This Week, March 04 – March 07, 2024
